Prevalence of Dyslipidemia and Availability of Lipid-Lowering Medications Among Primary Health Care Settings in China

Abstract

IMPORTANCE Dyslipidemia, the prevalence of which historically has been low in China, is emerging as the second leading yet often unaddressed factor associated with the risk of cardiovascular diseases. However, recent national data on the prevalence, treatment, and control of dyslipidemia are lacking.OBJECTIVE To assess the prevalence, treatment, and control of dyslipidemia in community residents and the availability of lipid-lowering medications in primary care institutions in China. DESIGN, SETTING, AND PARTICIPANTSThis cross-sectional study used data from the China-PEACE (Patient-Centered Evaluative Assessment of Cardiac Events) Million Persons Project, which enrolled 2 660 666 community residents aged 35 to 75 years from all 31 provinces in China between December 2014 and May 2019, and the China-PEACE primary health care survey of 3041 primary care institutions. Data analysis was performed from June 2019 to March 2021. EXPOSURES Study period. MAIN OUTCOMES AND MEASURES The main outcome was the prevalence of dyslipidemia, which was defined as total cholesterol greater than or equal to 240 mg/dL, low-density lipoprotein cholesterol (LDL-C) greater than or equal to 160 mg/dL, high-density lipoprotein cholesterol (HDL-C) less than 40 mg/dL, triglycerides greater than or equal to 200 mg/dL, or self-reported use of lipidlowering medications, in accordance with the 2016 Chinese Adult Dyslipidemia Prevention Guideline. RESULTS This study included 2 314 538 participants with lipid measurements (1 389 322 women [60.0%]; mean [SD] age, 55.8 [9.8] years). Among them, 781 865 participants (33.8%) had dyslipidemia. Of 71 785 participants (3.2%) who had established atherosclerotic cardiovascular disease (ASCVD) and were recommended by guidelines for lipid-lowering medications regardless of LDL-C levels, 10 120 (14.1%) were treated. The overall control rate of LDL-C (Յ70 mg/dL) among adults with established ASCVD was 26.6% (19 087 participants), with the control rate being 44.8% (4535 participants) among those who were treated and 23.6% (14 552 participants) among those not treated. Of 236 579 participants (10.2%) with high risk of ASCVD, 101 474 (42.9%) achieved LDL-C less than or equal to 100 mg/dL. Among participants with established ASCVD, advanced age (age 65-75 years, odds ratio [OR], 0.63; 95% CI, 0.56-0.70), female sex (OR, 0.56; 95% CI, 0.53-0.58), lower income (reference category), smoking (OR, 0.89; 95% CI, 0.85-0.94), alcohol consumption (OR, 0.87; 95% CI, 0.83-0.92), and not having diabetes (reference category) were associated with lower control of LDL-C. Among participants with high risk of ASCVD, younger age (reference category) and female sex (OR, 0.58; 95% CI, 0.56-0.59) were associated with lower control of LDL-C. (continued) Key Points Question What is the prevalence of dyslipidemia in Chinese adults and what are the treatment and control rates of elevated low-density lipoprotein cholesterol in both primary and secondary prevention populations? Findings In this cross-sectional study of 2 314 538 community r...

Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China

“…Second, benefiting from the centralized medicine procurement policy in China, the annual cost of treatment per patient with moderate-intensity statins has reduced from $300 to $50 ( 18 ), making the treatment more affordable. The next step should be to ensure that statins is more widely available, given its unavailability in nearly half of the primary care institutions, especially rural village clinics ( 29 ). Third, there are still around 11 million Chinese people at high or very-high ASCVD risk requiring ezetimibe and/or PCSK9 inhibitors; however, the prices of the two drugs in China (i.e., annual $380 for ezetimibe, and $5,182 for evolucumab 140 mg per patient) are even higher than those in some high-income countries ( 25 ).…”

Association Between Lipid Profiles and Left Ventricular Hypertrophy: New Evidence from a Retrospective Study

“…[14,15] It is noteworthy that high triglycerides and low HDL-c are the main types of dyslipidemia in the Chinese population, in contrast to the predominance of high TC and high LDL-c in the United States and Europe. [38] This feature suggests that management of triglycerides in the Chinese population may yield greater benefit. The role of triglycerides in the development of cardiovascular disease has received increasing attention in recent years, yet the protective effect of triglycerides control has been controversial.…”

Landscape of cardiometabolic risk factors in Chinese population: a narrative review

“…The nationwide study InterASIA in 2000–2001 provided the first glimpse into the prevalence of dyslipidemia in China, which found that 53.6% of adults aged 35–74 years had dyslipidemia, and in regard to its components, 9.0%, 5.1%, and 19.2% had high total cholesterol, high low-density lipoprotein cholesterol (LDL-C), and low high-density lipoprotein cholesterol (HDL-C), respectively [ 7 , 41 ]. Studies in 2014–2019 revealed a consistently high prevalence of dyslipidemia in China, ranging from 33.8 to 43% among adults of middle or senior ages; presentations with high triglycerides (16.9–22.4%) and low HDL-C (15.6–19.9%) were more common compared with high total cholesterol (7.1%–11.3%) and high LDL-C (4.0–8.1%) [ 42 – 44 ]. Among adults aged ≥ 18 years, the prevalence of high total cholesterol, high triglycerides, high LDL-C, and low HDL-C was reported to be 6.9%, 13.8%, 8.1%, and 20.4% in 2013–2014, respectively [ 45 ].…”